Business
Pharmagreen Prepares for Entry Into the Multi-Billion Dollar California Cannabis Industry
Pharmagreen Prepares for Entry Into the Multi-Billion Dollar California Cannabis Industry.
About this update from Pharmagreen Biotech Inc.
[{"type":"text","content":"\n CARSON CITY, NV, Nov. 11, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Pharmagreen Biotech, Inc., (OTC PINKS: PHBI), is pleased to announce that in advance of its entry into the multi-billion dollar California cannabis industry and the development of its Tissue Culture Centre, the company has engaged its research and development corporate partner to commence developing tissue culture protocol for each of the top Cannabis Strains sold and grown in California. This cannabis market is estimated to be over $6 Billion annually.  The cannabis strains targeted for protocol development (scientific process for plant reproduction where each strain has its own protocol) are some of the top strains currently being grown in California by cultivators.  California market is very unique with well established, highly experienced breeders for top Cannabis strains.  Their strains are never lacking in potency, flavor, or aesthetics.   Each strain development can take months to complete. Pharmagreen’s commencing the research on the development of the tissue culture protocols will provide a much faster time to full scale production of starter plantlets.  Pharmagreen adopting a vertically integrated business model, by getting a nursery license once the California acquisition is completed, the Golden State represents a significant opportunity. Few cannabis companies have recognized the importance of the cannabis nursery for providing a long-term path to increased market share statewide. Pharmagreen is looking to carve out a competitive advantage; the cannabis nursery license offers the ability to design and cultivate unique strains capable of differentiating ourselves from the competition.  A nursery license in California also allows the holder to sell those starter plants and seeds to another state cannabis license holder, including other nurseries, cultivators and processors. Controlling the entire supply chain from plantlet (tissue cultured starter plantlets) to sale (state of the art greenhouse grade A flower tops) gives Pharmagreen a high level of control over product quality. In this way, vertical integration enables us to target specific customer profiles, generating a higher rate of return with each strain and product design. Pharmagreen has a strong focus on genetics which al...